New Warning on Yaz Safety as Bayer Recommits to Settling Claims

The Drug Risk Resource Center is the Web’s most up-to-date source for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
DrugRisk Dangerous Drugs
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

New York, NY (PRWEB) November 20, 2012

The American College of Obstetricians and Gynecologists last month warned that birth control pills containing drospirenone such as Yaz and Yasmin may have a higher risk of causing blood clots, according to the Chicago Tribune on October 24, 2012.

The warning comes as German drug maker Bayer reported to investors that it will reserve an additional $262 million to settle Yaz and Yasmin lawsuits, which have now passed 13,500 claims. The news was reported in the Legal Notes section of the Bayer Interim Financial Statement, September 30, 2012.

Bayer also confirmed that it is only settling claims involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism, and has so far resolved about 3,490 injury claims at a total cost of nearly $750 million.

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

Bloomberg News had reported on July 31st that Bayer was settling cases at an average of nearly $212,000 per case, however, the most recent report indicates the amount could be slightly higher.

In October of 2011, the FDA released a study entitled "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints" which found that drugs like Yaz could increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.

A federal Multi-District Litigation court was established in Illinois to handle Yaz lawsuits filed by those injured. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois). The September 30 Bayer report indicates more than 13,500 patients have filed a claim.

The news of additional Yaz lawsuit settlements is positive for those injured who have yet to file a claim. However, time is limited and only certain cases may qualify.

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism and believes it may be due to taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

The Drug Risk Resource Center cautions that victims should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.


Contact